Issued Patents All Time
Showing 1–9 of 9 patents
| Patent # | Title | Co-Inventors | Date |
|---|---|---|---|
| 11439620 | Synergistic effect of anti-trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors | David M. Goldenberg | 2022-09-13 |
| 11253606 | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer | David M. Goldenberg | 2022-02-22 |
| 10988539 | Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers | David M. Goldenberg | 2021-04-27 |
| 10918734 | Treatment of high Trop-2 expressing triple negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51 | David M. Goldenberg | 2021-02-16 |
| 10709701 | Efficacy of anti-HLA-DR antibody drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers | Serengulam V. Govindan, David M. Goldenberg | 2020-07-14 |
| 10206918 | Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers | Serengulam V. Govindan, David M. Goldenberg | 2019-02-19 |
| 10195175 | Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors | David M. Goldenberg | 2019-02-05 |
| 10058621 | Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers | David M. Goldenberg | 2018-08-28 |
| 9707302 | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer | David M. Goldenberg | 2017-07-18 |